{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-053596","form_type":"8-K","ticker":null,"cik":"0001850079","company_name":"Telesis Bio Inc.","filed_at":"2024-05-06T23:59:59+00:00","discovered_at":"2026-05-14T18:03:20.814121+00:00","generated_at":"2026-06-02T22:24:56.893578+00:00","sec_items":["3.03","5.03","5.07","7.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Telesis Bio approves 1-for-18 reverse stock split to regain Nasdaq bid price compliance","bullets":["Reverse stock split at 1-for-18 ratio approved by stockholders on May 1, 2024; effective May 9, 2024.","Outstanding shares reduced from ~30.1M to ~1.7M; authorized shares remain at 100M.","Split intended to regain compliance with Nasdaq $1.00 minimum bid price requirement.","Ticker TBIO unchanged; new CUSIP 192003200; fractional shares rounded up to whole share."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-053596","json":"https://secwatch.observer/filing/0000950170-24-053596.json","markdown":"https://secwatch.observer/filing/0000950170-24-053596.md","text":"https://secwatch.observer/filing/0000950170-24-053596.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1850079/000095017024053596/0000950170-24-053596-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1850079/000095017024053596/tbio-20240501.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-02T22:24:56.893578+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"e09d7825bb66d6c3e50061e8f6cdddaf1cd89bf8","claim":"Telesis Bio Inc.: Effected a 1-for-18 reverse stock split by filing a Certificate of Amendment to the Amended and Restated Certificate of Incorporation (effective 2024-05-09).","evidence_excerpt":"the Company filed a Certificate of Amendment to the Amended and Restated Certificate of Incorporation (the Certificate of Amendment) with the Secretary of State of the State of Delaware on May 2, 2024 to effect a reverse stock split of the Company’s Common Stock, par value $0.0001 per share (the Common Stock) at a ratio of 1-for-18 (the Reverse Stock Split).","evidence_source":"SEC 8-K Item 5.03/5.05/5.06","evidence_url":"https://www.sec.gov/Archives/edgar/data/1850079/000095017024053596/0000950170-24-053596-index.htm","confidence":0.9,"family_label":"Governance Changes","details":[{"label":"Change","value":"charter amendment"},{"label":"Effective","value":"2024-05-09"}],"fact_type":"governance_change"},{"claim_id":"0480138f08d10b50648b471ed8a0406e84d12fd2","claim":"Telesis Bio Inc. shareholders approved Approve amendment to Certificate of Incorporation to effect a reverse stock split of Common Stock at ratio of 1-for-18 at the 2024-05-01 meeting.","evidence_excerpt":"For Against Abstain Broker Non-Votes 31,672,315 321,415 4,710 -","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1850079/000095017024053596/0000950170-24-053596-index.htm","confidence":0.9,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"reverse split"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2024-05-01"}],"fact_type":"shareholder_vote"},{"claim_id":"8c689f91f5c3f1312e8aa156760945da70f18137","claim":"Telesis Bio Inc. shareholders approved Ratify appointment of WithumSmith+Brown, PC as independent registered public accounting firm for fiscal year ending December 31, 2024 at the 2024-05-01 meeting.","evidence_excerpt":"For Against Abstain Broker Non-Votes 31,935,240 38,807 24,390 -","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1850079/000095017024053596/0000950170-24-053596-index.htm","confidence":0.9,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"auditor ratification"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2024-05-01"}],"fact_type":"shareholder_vote"},{"claim_id":"b2462e90c993f5688a3953ef2909a9b07143afc2","claim":"Telesis Bio Inc. shareholders approved Election of three Class III directors to serve until the 2027 annual meeting at the 2024-05-01 meeting.","evidence_excerpt":"Nominee Votes For Votes Withheld Percent of Voted Broker Non-Votes Christine A. Tsingo 31,921,084 77,353 99.76% - Jami Nachtsheim 31,847,171 150,037 99.53% 1,229 Annette Tumolo 31,921,201 77,236 99.76% -","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1850079/000095017024053596/0000950170-24-053596-index.htm","confidence":0.9,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"director election"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2024-05-01"}],"fact_type":"shareholder_vote"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}